Core Viewpoint - Ionis has made significant progress over the past few years, positioning itself for substantial growth and value creation for stakeholders in the coming years [2]. Group 1: Company Evolution - Six years ago, Ionis transitioned from an R&D organization to a fully integrated commercial-stage biotechnology company [3]. - The company aims to drive substantial accelerating growth and value for all stakeholders [2]. Group 2: Leadership and Vision - Brett Monia has been the CEO of Ionis for nearly seven years and emphasizes the remarkable progress made during this time [2]. - The focus is on leveraging the momentum built over the last few years to achieve greater success [2].

Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **CEO**: Brett Monia - **Conference Date**: January 13, 2026 Key Industry Insights - Ionis has transitioned from an R&D organization to a fully integrated commercial biotechnology company, achieving its first two independent commercial launches in 2025: **Tringulza** and **Donzera** [4][5] - The company has a robust pipeline with **11 medicines in phase 3 development**, indicating a strong future for product approvals and revenue growth [6] Core Products and Launches - **Tringulza**: Approved for familial chylomicronemia syndrome (FCS), generating **$105 million** in net U.S. product sales in 2025 [13] - **Donzera**: Approved for hereditary angioedema (HAE) prophylaxis, launched in September 2025, with positive early prescription trends [8][9] - **Olezarsen**: Positioned as a new standard of care for severe hypertriglyceridemia (SHTG), with a peak revenue potential now upgraded to **over $2 billion** [17][35] Clinical Achievements - Six positive phase 3 data readouts leading to four approved medicines: Tringulza, Donzera, Wainua, and Qalsody [6] - Olezarsen demonstrated a **72% reduction** in fasting triglycerides and an **85% reduction** in acute pancreatitis event rates at 12 months [15][16] - Zolexarsen for Alexander disease shows unprecedented disease-modifying impact, with plans for NDA submission and launch in the second half of 2026 [21][24] Financial Projections - Anticipated **$4 billion** in potential annual peak product revenue from wholly owned pipeline and **$2 billion** from partner medicines, totaling **over $6 billion** at peak [26] - Expected to achieve cash flow break-even by **2028** with sustained positive cash flow thereafter [26] Market Strategy and Launch Preparations - The launch strategy for Olezarsen in SHTG is based on strong physician enthusiasm and a high unmet need, with a field team of **200 individuals** already hired and trained [33][31] - Pricing strategy for Olezarsen is projected between **$10,000 to $20,000** in the U.S., with ongoing engagement with payers to ensure access [37][38] Risks and Challenges - New product launches inherently carry uncertainty, but the demand for Olezarsen is expected to be strong due to the inadequacy of current treatments for SHTG [36] - The company is preparing for potential challenges in achieving broad access and acceptance among healthcare providers [37] Future Outlook - Ionis is well-positioned for continued growth with a steady cadence of new medicines expected to reach the market, including Olezarsen and Zolexarsen in 2026 [24][25] - The company aims to leverage its strong pipeline and market presence to drive revenue growth and enhance shareholder value [28]

44th Annual J.P. Morgan Healthcare Conference 2026 Breakthrough Therapies Driving Accelerating Growth Brett Monia, Ph.D. Chief Executive Officer January 2026 | Nasdaq: IONS Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement desc ...

Core Viewpoint - The article discusses the revolutionary shift in small nucleic acid drugs, highlighting their potential to transition from symptomatic treatment to addressing root causes, marking a significant advancement in the pharmaceutical industry [4]. Group 1: Small Nucleic Acid Drug Technology - Small nucleic acid drugs (siRNA, ASO, etc.) are considered the "third wave" of drug development, following small molecules and antibody drugs [4]. - These drugs are not limited by their molecular structure and can target a broader range of disease pathways, significantly increasing the probability of successful drug development [4]. - Current advancements in delivery technologies and chemical modifications have led to extended half-lives for these drugs, improving patient compliance in chronic disease management [4]. Group 2: Market Growth and Commercialization - The global small nucleic acid drug market is projected to reach $20.6 billion by 2029 and $54.9 billion by 2034, with a compound annual growth rate (CAGR) of 21.6% [5]. - Major players like Alnylam, Ionis, and Arrowhead are leading the market, with multinational corporations (MNCs) such as Novartis and Roche investing heavily in this sector [5]. - Alnylam's core product, Amvuttra, is expected to exceed $2 billion in sales by 2025, indicating strong market performance [6]. Group 3: Technological Breakthroughs - Arrowhead has developed RNAi therapies targeting various diseases through its TRiM platform, expanding the application of small nucleic acid drugs beyond liver diseases [7]. - Avidity Biosciences has made significant progress in muscle tissue delivery using antibody-oligonucleotide conjugates (AOC) technology, indicating a broader therapeutic potential [7]. Group 4: China's Small Nucleic Acid Drug Industry - The Chinese small nucleic acid drug industry is experiencing a qualitative leap, overcoming delivery patent barriers and demonstrating global competitiveness in target selection and molecular design [8]. - A complete industrial chain has emerged in China, with domestic raw materials achieving localization, thus reducing R&D costs [8]. - Significant business development (BD) transactions have occurred, including a record $5 billion deal between Wobang Pharmaceutical and Novartis, showcasing the global recognition of Chinese innovation [8].

Core Insights - GSK shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, for bepirovirsen, an investigational treatment for chronic hepatitis B, involving over 1,800 patients [1] - The studies met their primary endpoint, showing a statistically significant and clinically meaningful functional cure rate for bepirovirsen compared to standard care alone [3] - If approved, bepirovirsen could become the first finite, six-month therapeutic option for chronic hepatitis B [5] Financial and Partnership Details - Ionis received an upfront payment, license fee, and development milestone payments from GSK, with potential additional payments of $150 million and tiered royalties of 10-12% on net sales of bepirovirsen [2] - The collaboration between Ionis and GSK began in 2019 when GSK licensed bepirovirsen from Ionis [1] Study Results and Future Plans - The B-Well studies demonstrated an acceptable safety and tolerability profile consistent with previous studies, with full results to be presented at a scientific congress and submitted for regulatory approvals in early 2026 [4] - The studies showed significantly higher functional cure rates in patients with baseline surface antigen levels ≤1000 IU/ml [3] Analyst Commentary - Analysts from William Blair noted that Ionis is well-positioned with five Phase 3 readouts expected in 2026, highlighting bepirovirsen as an underappreciated opportunity in the market [6] - The performance of Gilead Science's Vemlidy, projected to exceed $1 billion in revenue for fiscal 2025, suggests a growing market for hepatitis B treatments [6] Market Reaction - Following the announcement, Ionis Pharmaceuticals shares increased by 4.06% to $84.80, while GSK shares rose by 1.20% to $51.16 [8]

Core Insights - GSK announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B treatment [1] Company Summary - Ionis Pharmaceuticals partnered with GSK for the development of bepirovirsen, which has shown promising safety and efficacy results in over 1,800 patients across 29 countries [1]

Core Viewpoint - Ionis Pharmaceuticals, Inc. will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 8:15 a.m. PT [1] Company Information - The presentation will be led by Brett P. Monia, Ph.D., the chief executive officer of Ionis Pharmaceuticals [1] - A live webcast of the presentation will be available on the Investors & Media section of the Ionis website [1] - A replay of the presentation will be accessible on the Ionis website within 48 hours after the event [1]

Core Insights - Oligonucleotide therapies are emerging as a significant breakthrough in the treatment of rare diseases, with over a dozen therapies approved globally and hundreds in clinical research, promising to benefit more patients in the future [1][14][15] Industry Developments - The global landscape has seen more than ten oligonucleotide therapies approved for rare diseases, providing new treatment options for conditions such as Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), and Hemophilia [1][14] - There are currently over a hundred oligonucleotide therapies in clinical development targeting various rare diseases, including siRNA and antisense oligonucleotide (ASO) therapies [2][14] Recent Approvals and Innovations - In August, Ionis Pharmaceuticals received FDA approval for the LICA drug Dawnzera (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older, marking it as the first RNA-targeted drug for HAE [4][18] - Ionis Pharmaceuticals and Sobi announced the approval of ASO drug Tryngolza (olezarsen) in the EU for treating genetically confirmed familial chylomicronemia syndrome (FCS) [4][19] - Alnylam Pharmaceuticals' siRNA therapy Amvuttra (vutrisiran) was approved by the FDA in March for treating patients with transthyretin amyloidosis with cardiomyopathy [5][19] Clinical Trial Progress - NS Pharma reported positive results from the long-term extension study of ASO therapy brogidirsen for DMD, showing effective exon 44 skipping and stable maintenance of motor function in patients [7][21] - RIBOMIC's umedaptanib pegol showed promising results in a Phase 2 trial for achondroplasia in children, with many patients experiencing improved height growth rates [7][21] - Ionis Pharmaceuticals' ASO therapy zilganersen demonstrated significant results in stabilizing walking speed in Alexander disease patients, with plans for a new drug application to the FDA in 2026 [8][22] WuXi TIDES Platform - WuXi TIDES has established an integrated solution for oligonucleotide and peptide therapies, covering custom synthesis, conjugation, process development, and CMC, facilitating the transition of innovative projects into clinical stages [1][11][26] - The platform offers comprehensive CRDMO services from drug discovery to commercial production, supporting high-throughput synthesis and custom synthesis for various oligonucleotides [11][26][27] Future Outlook - The company aims to continue leveraging its integrated CRDMO model to empower the development of various new drugs, including oligonucleotide therapies, to bring more effective treatments to patients [12][27]

Core Viewpoint - AstraZeneca announced the approval of Ipupronit Sodium Injection (brand name Wainua) in China for the treatment of adult hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN), marking a significant milestone as it is the only gene-silencing agent approved for this condition in the country [1][6]. Group 1: Approval and Treatment Benefits - The approval is based on positive results from the NEURO-TTRansform Phase III clinical study, which demonstrated consistent and sustained clinical benefits in patients treated with Ipupronit Sodium compared to a placebo over a 66-week observation period [3][8]. - Key endpoints showed improvements in serum transthyretin (TTR) levels and neuropathy impairment scores, as well as quality of life assessments, indicating the drug's effectiveness [3][8]. Group 2: Disease Context and Treatment Mechanism - ATTRv-PN is a debilitating disease that can lead to peripheral nerve damage, with patients typically experiencing motor function impairment within five years of diagnosis and an average life expectancy of ten years without treatment [4][9]. - Ipupronit Sodium is administered monthly via an automatic injector, enhancing medication convenience and potentially improving patients' quality of life [1][6]. - The drug works by upstream inhibition of TTR production in the liver, making it a promising treatment for various types of transthyretin amyloidosis [4][9]. Group 3: Global Development and Ongoing Research - Ipupronit Sodium has also been approved in the United States and the European Union, with ongoing efforts to secure approvals in more countries [5][9]. - The drug is currently undergoing the CARDIO-TTRansform Phase III clinical study to evaluate its efficacy in treating adult transthyretin cardiac amyloidosis (ATTR-CM), which is the largest clinical study of its kind with over 1,400 participants [5][9].

Core Insights - AstraZeneca and Ionis Pharmaceuticals have jointly developed Ipupronit Sodium Injection, which has been approved by the National Medical Products Administration for the treatment of adult patients with hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN) [1] - Ipupronit Sodium is the first and currently the only gene-silencing agent approved for the treatment of ATTRv-PN in China [1] Group 1: Disease Overview - ATTR is caused by the accumulation of misfolded TTR protein produced by the liver, leading to organ damage and failure, with various complications affecting cardiovascular, neurological, and renal health [2] - ATTR has multiple phenotypes, including ATTR-CM (primarily affecting the heart) and ATTRv-PN (primarily affecting the peripheral nervous system), with ATTRv-PN being a debilitating disease that can lead to motor function impairment within five years of diagnosis [2] - The average age of onset for patients in China is 42 years, with a range from 17 to 68 years, and there is a significant delay of 3 to 4 years from symptom onset to diagnosis due to low awareness among the public and healthcare professionals [2] Group 2: Treatment Insights - Ipupronit Sodium is a gene-silencing agent administered once a month, which works by upstream inhibition of TTR protein production, showing potential for treating various types of transthyretin amyloidosis [3] - The approval of Ipupronit Sodium provides new hope for ATTRv-PN patients, as clinical evidence indicates it can halt the progression of neuropathy and significantly improve neurological function and quality of life [3]